Respivant Sciences GmbH
Records under this name other than patents Respivant Sciences GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Respivant Sciences GmbH
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,968,586 | Mast cell stabilizers treatment for systemic disorders Formerly held Lapsed on the fee record Ended May 15, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 15, 2026 | From the USPTO record |
| US 9,962,363 | Mast cell stabilizers treatment for systemic disorders Lapsed on the fee record Ended May 8, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 8, 2026 | From the USPTO record |
| US 9,707,206 | Mast cell stabilizers treatment for systemic disorders Formerly held Lapsed on the fee record Ended Jul 18, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jul 18, 2025 | From the USPTO record |
| US 10,835,512 | Methods of treating respiratory syncytial virus infections Lapsed on the fee record Ended Nov 17, 2024 · From the USPTO record | Lapsed on the fee record | Ended Nov 17, 2024 | From the USPTO record |
| US 10,596,146 | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders Lapsed on the fee record Ended Mar 24, 2024 · From the USPTO record | Lapsed on the fee record | Ended Mar 24, 2024 | From the USPTO record |
| US 10,583,113 | Cromolyn compositions for treatment of pulmonary fibrosis Lapsed on the fee record Ended Mar 10, 2024 · From the USPTO record | Lapsed on the fee record | Ended Mar 10, 2024 | From the USPTO record |
| US 9,265,749 | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders Formerly held Lapsed on the fee record Ended Feb 23, 2024 · From the USPTO record | Lapsed on the fee record | Ended Feb 23, 2024 | From the USPTO record |
| US 10,561,635 | Cromolyn compositions for treatment of pulmonary fibrosis Lapsed on the fee record Ended Feb 18, 2024 · From the USPTO record | Lapsed on the fee record | Ended Feb 18, 2024 | From the USPTO record |
| US 10,463,613 | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis Formerly held Lapsed on the fee record Ended Nov 5, 2023 · From the USPTO record | Lapsed on the fee record | Ended Nov 5, 2023 | From the USPTO record |
| US 10,398,673 | Mast cell stabilizers treatment for systemic disorders Formerly held Lapsed on the fee record Ended Sep 3, 2023 · From the USPTO record | Lapsed on the fee record | Ended Sep 3, 2023 | From the USPTO record |